Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

FCH domain only 1 (FCHo1), a potential new biomarker for lung cancer


Lung carcinoma is the main reason for cancer-associated deaths in the world. In a previous study, FCH domain only 1 (FCHo1) which is managed by protein kinase B (AKT), was shown to be activated in lung cancer. FCHo1 knockdown has previously been shown to cause cell death in lung cancer. However, the specific roles of FCHo1 in lung carcinoma remain elusive. Herein, we propose that FCHo1’s intracellular mechanism targets the G1 to S phase transition, following the M phase. We demonstrated that F-BAR and mu homology domains exist separately in human lung tissues and that one truncated form is not detected in patients with lung cancer. Furthermore, quantitative global proteome analysis of FCHo1 indicated that the inhibition of G1/S phase transition and FCHo1 RNAi led to the death of cells in the G1/S phase. Noninvasive viral aerosol-mediated delivery of FCHo1 shRNA suppressed cancer progression in mice with non-small-cell lung cancer (NSCLC), suggesting that the delivery of FCHo1 shRNA could be a meaningful therapeutic strategy in lung cancer. Additional studies are needed to make clear the detailed mechanism of action of FCHo1.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Truncated FCHo1 has a different distribution in lung cancer patients.
Fig. 2: Quantitative global proteome analysis in FCHo1-overexpressing A549 cells.
Fig. 3: FCHo1 siRNA leads to cell death in A549 lung cancer cells during the cell cycle.
Fig. 4: FCHo1 shRNA inhibits lung tumorigenesis in K-RasLA1 mice.


  1. Henne WM, Boucrot E, Meinecke M, Evergren E, Vallis Y, Mittal R, et al. FCHo proteins are nucleators of clathrin-mediated endocytosis. Science 2010;328:1281–4.

    CAS  Article  Google Scholar 

  2. Henne WM, Kent HM, Ford MGJ, Hegde BG, Daumke O, Butler PJG, et al. Structure and analysis of FCHo2F-BAR domain: a dimerizing and membrane recruitment module that effects membrane curvature. Structure 2007;15:839–52.

    CAS  Article  Google Scholar 

  3. Lyszkiewicz M, Zietara N, Frey L, Pannicke U, Stern M, Liu Y, et al. Human FCHO1 deficiency reveals role for clathrin-mediated endocytosis in development and function of T cells. Nat Commun. 2020;11:1031.

    CAS  Article  Google Scholar 

  4. Umasankar PK, Sanker S, Thieman JR, Chakraborty S, Wendland B, Tsang M, et al. Distinct and separable activities of the endocytic clathrin-coat components Fcho1/2 and AP-2 in developmental patterning. Nat Cell Biol. 2012;14:488–501.

    CAS  Article  Google Scholar 

  5. Park S, Hong Y, Lee S, Lee AY, Tran Q, Lee H. et al. FCHO1560-571 peptide, a PKB kinase motif, inhibits tumor progression. Biochem Biophys Res Commun. 2020;528:478–484.

    CAS  Article  Google Scholar 

  6. Aviner R, Shenoy A, Elroy-Stein O, Geiger T. Uncovering hidden layers of cell cycle regulation through integrative multi-omic analysis. PLoS Genet. 2015;11(10):e1005554.

  7. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008;15:1153–62.

    CAS  Article  Google Scholar 

  8. Chieffi P, Aurora B. A new promising therapeutic target in cancer. Intractable Rare Dis Res. 2018;7:141–4.

    Article  Google Scholar 

  9. McDonald NA, Takizawa Y, Feoktistova A, Xu P, Ohi MD, Vander Kooi CW, et al. The tubulation activity of a fission yeast F-BAR protein is dispensable for its function in cytokinesis. Cell Rep. 2016;14:534–46.

    CAS  Article  Google Scholar 

  10. Finkel T, Hwang PM. The Krebs cycle meets the cell cycle: mitochondria and the G(1)-S transition. Proc Natl Acad Sci USA. 2009;106:11825–6.

    CAS  Article  Google Scholar 

  11. Sugiyama M, Sakaue-Sawano A, Iimura T, Fukami K, Kitaguchi T, Kawakami K, et al. Illuminating cell-cycle progression in the developing zebrafish embryo. Proc Natl Acad Sci USA. 2009;106:20812–7.

    CAS  Article  Google Scholar 

  12. Wragg JW, Roos L, Vucenovic D, Cvetesic N, Lenhard B, Mueller F. Zebrafish embryonic tissue differentiation is marked by concurrent cell cycle dynamic and gene promoter regulatory changes. 2020;48(15):8374-8392.

  13. Bavetsias V, Linardopoulos S. Aurora kinase inhibitors: current status and outlook. Front Oncol. 2015;5:278.

  14. Hong SH, Chang SH, Cho KC, Kim S, Park S, Lee AY, et al. Endoplasmic reticulum–Golgi intermediate compartment protein 3 knockdown suppresses lung cancer through endoplasmic reticulum stress-induced autophagy. Oncotarget 2016;7:65335–47.

    Article  Google Scholar 

  15. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–62.

    CAS  Article  Google Scholar 

  16. Hoerth P, Miller CA, Preckel T, Wenz C. Efficient fractionation and improved protein identification by peptide OFFGEL electrophoresis. Mol Cell Proteom. 2006;5:1968–74.

    CAS  Article  Google Scholar 

  17. Searle BC. Scaffold: a bioinformatic tool for validating MS/MS-based proteomic studies. Proteomics 2010;10:1265–9.

    CAS  Article  Google Scholar 

  18. Chang S-H, Hong S-H, Jiang H-L, Minai-Tehrani A, Yu K-N, Lee J-H, et al. GOLGA2/GM130, cis-Golgi matrix protein, is a novel target of anticancer gene therapy. Mol Ther. 2012;20:2052–63.

    CAS  Article  Google Scholar 

  19. Hong S-H, Minai-Tehrani A, Chang S-H, Jiang H-L, Lee S, Lee A-Y, et al. Knockdown of the sodium-dependent phosphate co-transporter 2b (NPT2b) suppresses lung tumorigenesis. PLoS ONE. 2013;8:e77121.

    CAS  Article  Google Scholar 

  20. Hong S-H, Park S-J, Lee S, Cho CS, Cho M-H. Aerosol gene delivery using viral vectors and cationic carriers for in vivo lung cancer therapy. Expert Opin Drug Deliv. 2015;12:977–91.

    CAS  Article  Google Scholar 

  21. Islam MA, Shin J-Y, Yun C-H, Cho C-S, Seo HW, Chae C, et al. The effect of RNAi silencing of p62 using an osmotic polysorbitol transporter on autophagy and tumorigenesis in lungs of K-ras(LA1) mice. Biomaterials 2014;35:1584–96.

    CAS  Article  Google Scholar 

Download references


This work was supported by BK21 PLUS Program for Creative Veterinary Science Research. This work was financially supported by a research fund from Chungnam National University (grant to JP).

Author information

Authors and Affiliations



SP, JP, and MHC designed the entire study and wrote the manuscript. SP and AYL performed experiments including immunoprecipitations, live cell imaging, RTCA proliferation assays, lentivirus production, and DNA construct cloning, and contributed equally to the data interpretation and the writing and preparation of the manuscript. AYL, SK, and SHH performed the in vivo experiment. KCC and JHJ performed the proteomics analysis and contributed to data interpretation and manuscript preparation. JP, KPK, and MHC jointly supervised the study. All authors discussed the results and reviewed the manuscript.

Corresponding authors

Correspondence to Kwang Pyo Kim, Jongsun Park or Myung-Haing Cho.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Park, S., Lee, A.Y., Cho, KC. et al. FCH domain only 1 (FCHo1), a potential new biomarker for lung cancer. Cancer Gene Ther 29, 901–907 (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links